KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) EBIT (2016 - 2025)

Historic EBIT for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to -$60.2 million.

  • Supernus Pharmaceuticals' EBIT fell 24746.24% to -$60.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$36.9 million, marking a year-over-year decrease of 16233.19%. This contributed to the annual value of $81.7 million for FY2024, which is 164993.36% up from last year.
  • Per Supernus Pharmaceuticals' latest filing, its EBIT stood at -$60.2 million for Q3 2025, which was down 24746.24% from $12.1 million recorded in Q2 2025.
  • In the past 5 years, Supernus Pharmaceuticals' EBIT ranged from a high of $40.8 million in Q3 2024 and a low of -$60.2 million during Q3 2025
  • In the last 5 years, Supernus Pharmaceuticals' EBIT had a median value of $8.1 million in 2023 and averaged $7.9 million.
  • As far as peak fluctuations go, Supernus Pharmaceuticals' EBIT plummeted by 25500.62% in 2023, and later surged by 224909.64% in 2024.
  • Over the past 5 years, Supernus Pharmaceuticals' EBIT (Quarter) stood at $6.1 million in 2021, then surged by 463.04% to $34.3 million in 2022, then plummeted by 102.9% to -$996000.0 in 2023, then surged by 2249.1% to $21.4 million in 2024, then plummeted by 381.39% to -$60.2 million in 2025.
  • Its last three reported values are -$60.2 million in Q3 2025, $12.1 million for Q2 2025, and -$10.3 million during Q1 2025.